BIRC3 and B-cell chronic lymphocytic leukemia: BIRC3-disrupting mutations and deletions have been rarely detected in CLL at diagnosis (4%) but are detected in 24% of fludarabine-refractory CLL patients, suggesting that BIRC3 genetic lesions are specifically associated with a chemo-refractory CLL phenotype [60,61].